Tab Application Banner
  • Users Online: 1332
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2015  |  Volume : 10  |  Issue : 5  |  Page : 64-71

Polyarteritis nodosa - Challenges and options in management


1 Division of Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada
2 Division of Rheumatology, Vasculitis Clinic, McMaster University, St. Joseph's Healthcare, Hamilton, Ontario, Canada

Correspondence Address:
Christian Pagnoux
Division of Rheumatology, Vasculitis Clinic, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.injr.2015.08.002

Rights and Permissions

Polyarteritis nodosa (PAN) was one of the first systemic necrotizing vasculitides to be described, in the late 19th century. Hepatitis B virus (HBV) was the major cause of the observed PAN cases between 1970 and the early 2000s. However, in the revised 2012 Chapel Hill Consensus Conference nomenclature, HBV-related PAN is now included with vasculiti- des associated with probable etiologies (and named HBV-associated vasculitis). PAN should thus now refer exclusively to primary cases, without an identified or probable cause. Besides systemic forms of the primary and ''classical'' PAN, which have become more rare over the past decade, isolated and/or single organs can be affected, including the skin. In this article, we review the main clinical, biological, and radiological characteristics of ''classical'' primary PAN and its different forms, their treatment options, and outcomes. We also discuss other possible etiologies (other than HBV) of PAN-like medium-sized vessel vasculi- tis and newly described PAN-like vasculopathies, such as recessive loss-of-function muta- tions in adenosine deaminase 2, as well as the treatment options for isolated or refractory cases and the current place of biologic agents for the treatment of PAN.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed584    
    Printed8    
    Emailed0    
    PDF Downloaded162    
    Comments [Add]    
    Cited by others 1    

Recommend this journal